Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A fresh boost in Pfizer’s stock reflects how quickly sentiment can turn when investors judge a large healthcare name as both battered enough to hold support and volatile enough to move on headlines.
THE APEX TIMES
THE APEX TIMES
A widely circulated market note argues Pfizer’s shares could re-rate toward $50 if multiple expansion returns, even as revenue declines tied to Comirnaty and Paxlovid continue to weigh on sentiment.
THE APEX TIMES
The U.S. FDA has broadened HYMPAVZI’s label for pediatric patients with hemophilia A and B, adding children as young as six and refining its positioning across cases with and without inhibitors.
THE APEX TIMES
The reported agreement gives Amneal a pathway to participate in the booming GLP-1 supply chain through manufacturing collaboration with Pfizer, while also positioning it for higher-value products like biosimilars. Pfizer’s involvement, however, is still light on specifics in public reporting.
THE APEX TIMES
With blockbuster COVID-era earnings largely behind it, Pfizer is banking on newly built and acquired weight-loss efforts to offset major exclusivity losses coming in 2026 and 2027.
THE APEX TIMES
The approval broadens HYMPAVZI (marstacimab-hncq) to include hemophilia patients with inhibitors and adds younger pediatric patients, reinforcing Pfizer’s push for non-factor, once-weekly prophylaxis.
THE APEX TIMES
At the American Diabetes Association’s 2026 Scientific Sessions, investors weighed new clinical updates from Eli Lilly, Pfizer, and Roche as the obesity drug market prepares for more entrants beyond the current leaders.
THE APEX TIMES
The deal gives Pfizer early access to Chai-3 and a custom version of the platform built with Pfizer’s proprietary data, as the two companies move from AI research toward deployment inside drug discovery workflows.
THE APEX TIMES
The pharmaceutical company says it will gain early access to Chai-3 and deploy the platform inside its drug-discovery workflow, with Chai citing a doubling of antibody design success versus its prior model.
